Anti-adalimumab Antibodies in Patients with Non-infectious Ocular Inflammatory Disease: A Case Series

References

• Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–637. doi:10.1016/j.preteyeres.2004.06.005.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis (VISUAL I). N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646. doi:10.1056/NEJMoa1614160.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. J Am Med Assoc. 2019;322(10):936–945. doi:10.1001/jama.2019.12618.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634–641. doi:10.1001/archopht.123.5.634.
   PubMedGoogle Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–509.e2. doi:10.1016/j.ajo.2009.05.008.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.e1. doi:10.1016/j.ophtha.2009.04.020.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316. doi:10.1007/s40259-017-0231-8.
   PubMed Web of Science ®Google Scholar
• Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241–258. doi:10.1007/s40259-015-0134-5.
   PubMed Web of Science ®Google Scholar
• Alawadhi A, Alawneh K, Alzahrani ZA. The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what’s in it for African and Middle Eastern rheumatologists. Clin Rheumatol. 2012;31(9):1281–1287. doi:10.1007/s10067-012-2040-2.
   PubMed Web of Science ®Google Scholar
• Korswagen LA, Bartelds GM, Krieckaert CLM, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011;63(4):877–883. doi:10.1002/art.30209.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up. J Am Med Assoc. 2011;305(14):1460–1468. doi:10.1001/jama.2011.406.
   PubMed Web of Science ®Google Scholar
• Menting SP, Van Lümig PPM, De Vries ACQ, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis one-year follow-up. JAMA Dermatol. 2014;150(2):130. doi:10.1001/jamadermatol.2013.8347.
   PubMed Web of Science ®Google Scholar
• Laine J, Sakari Jokiranta T, Eklund KK, Väkeväinen M, Puolakka K. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers. Biol Targets Ther. 2016;67. doi:10.2147/BTT.S96982.
   PubMedGoogle Scholar
• Krieckaert CLM, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects Handling editor Tore K Kvien. Ann Rheum Dis. 2015;74(2):361–8. doi:10.1136/annrheumdis-2013-204101.
   Google Scholar
• Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016;123(12):2618–2625. doi:10.1016/j.ophtha.2016.08.025.
   PubMed Web of Science ®Google Scholar
• Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017;35(6):1043–1046.
   Google Scholar
• Llorenç V, Cordero-Coma M, Blanco-Esteban A, et al. Drug retention rate and causes of discontinuation of adalimumab in uveitis: Real-world data from the Biotherapies in Uveitis (BioÚvea) study group.Ophthalmology.2020;127(6):814–825. doi:10.1016/j.ophtha.2019.11.024.
   Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - Algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51. doi:10.1111/apt.13445.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(7):542–553. doi:10.1016/S1542-3565(04)00238-1.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s Disease. Gastroenterology. 2004;126(2):402–413. doi:10.1053/j.gastro.2003.11.014.
   PubMed Web of Science ®Google Scholar
• Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: case series and review of literature. World J Gastrointest Pharmacol Ther. 2017;8(3):155. doi:10.4292/wjgpt.v8.i3.155.
   PubMedGoogle Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. doi:10.1002/art.39480.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834. doi:10.1053/j.gastro.2017.07.032.
   PubMed Web of Science ®Google Scholar
• Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66(7):893–899. doi:10.1136/ard.2006.068304.
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent. J Am Acad Dermatol. 2016;75(3):612–618.e6. doi:10.1016/j.jaad.2016.02.1221.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle M, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015;17(1):1. doi:10.1186/s13075-015-0516-6.
   PubMedGoogle Scholar
• Van Schie KA, Hart MH, De Groot ER, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311–314. doi:10.1136/annrheumdis-2014-206237.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Van De Stadt LA, De Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104–109. doi:10.1136/annrheumdis-2012-201445.
   PubMed Web of Science ®Google Scholar